Ivastine (Rivastigmine)

Rivastigmine is a reversible inhibitor of both acetylcholinesterase and butyrylcholinesterase. By blocking these enzymes, it prevents the breakdown of acetylcholine, increasing its concentration in the brain. The higher acetylcholine levels support neuronal communication involved in learning, memory, and attention.

The prescribed dose of Ivastine is determined by the treating physician based on the patient’s clinical condition and tolerability. Typically, treatment starts with a low‑strength transdermal patch and may be titrated upward, with each patch replaced once every 24 hours as directed by the prescriber.

Safety data for rivastigmine during pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers usually advise against routine use in pregnant or nursing women.

To place an order, submit an enquiry on the Ivastine product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled requirements), and necessary import documentation.

Ivastine (rivastigmine) is a cholinesterase inhibitor similar to donepezil and galantamine but is available as a transdermal patch, which can improve adherence and reduce gastrointestinal side effects. Its dual inhibition of acetylcholinesterase and butyrylcholinesterase may offer broader enzyme coverage, though clinical choice depends on patient tolerance, comorbidities, and physician preference.

Ivastine patches should be stored at room temperature, below 25 °C, in their original sealed packaging. Protect them from moisture, direct sunlight, and excessive heat. Do not expose the patches to freezing temperatures, and keep them out of reach of children.

The patch is applied to clean, dry, hair‑free skin on the upper back, chest, or upper arm. Once applied, it should remain in place for 24 hours before being removed and replaced with a new patch at a different site to avoid skin irritation. Hands should be washed after handling the patch.

Serious adverse events include severe skin reactions such as rash or bullous dermatitis, significant bradycardia or syncope, and gastrointestinal bleeding or ulceration. Patients should be instructed to seek immediate medical attention if they experience any of these symptoms while using the patch.

Ivastine is contraindicated in individuals with known hypersensitivity to rivastigmine or any patch components, severe cardiac conduction disorders (e.g., sick‑sinus syndrome), active skin disease at the intended application site, or in patients who have experienced severe cholinergic toxicity with other cholinesterase inhibitors.